#featureed

The Trespass Offering

6:1 (5:20)

And Adonai spoke to Mosheh, saying:

6:2 (5:21) If a nefesh (person) sin, and commit a trespass against Adonai (יהוה), and lie to his neighbor in that which was delivered him to keep, or in fellowship, or in a thing taken away by violence, or has deceived his neighbor;

6:3 (5:22) Or have found that which was lost, and lies concerning it, and swears falsely; in any…

Confusion as Returning Officer announces result of election, fails to declare winner

Confusion as Returning Officer announces result of election, fails to declare winner.

The All Progressives Congress (APC) on Tuesday garnered the highest total votes cast for the Bauchi South Senatorial District but the Returning Officer, Prof. Ahmed Sarkin-Fagam, could not declare a winner for the election.

Announcing the result in Bauchi, Sarkin-Fagam, a lecturer with Abubakar Tafawa Balewa…

Davido welcomed like a President at NYSC camp as he starts his service.

Nigerian Music star, David Adeleke best known in showbiz as Davido was welcomed like a president at NYSC camp in Nigeria as he kick starts  his service. see photos below:

The 2018 B.E.T best international act announced on social media his plans to start his National service and it happens to be today.

The 30billion dollar musician tweeted on twitter today saying “Arriving at camp today” as he…

While the future of cannabusiness is certainly bright, one controversial yet crucial caveat must be made. Pot stocks should be treated as an agricultural commodity investment rather than as a biotech investment. This is not to say that cannabis cannot be used as a pharmaceutical. It certainly can. Rather it should not be invested in as one would invest in a pharmaceutical. Taking a biotech strategy with pot stocks is the wrong road to take.

  While this may be difficult for some to accept, the reasoning is as follows. The current hot case under discussion in the world of pot stocks revolves around GW Pharmaceuticals (GWPH) and Insys (INSY), which are squaring off in a race to develop the first FDA approved cannabidiol compound. Cannabidiol, otherwise known as CBD, is a cannabinoid compound found naturally in some marijuana strains that has medicinal properties without the accompanied psychoactivity of THC. Both companies have received orphanstatus from the FDA, and both are going after rare indications Dravet and Lennox-Gestault syndromes, two forms of childhood epilepsy together totaling a 20,000 US patient population.

  The buzz surrounding these two companies is understandable considering the astronomical movements in their share prices since 2013. Insys has increased by 528%, and GW 868% since its IPO in May 2013. The move in Insys is more reasonable considering the company rocketed into profitability with its revenues exploding to over $40M quarterly from just over $15M in all of 2012. As for GW, it seems to be all hype and projection, coupled with some excitement over the possibility of approval for Epidiolex, the company’s CBD candidate for which it was granted Orphan status. GW has never been profitable nor does it expect to be within the next decade as it continues to incur high drug development costs.

  And herein lies the problem of seeing pot stocks as biotechs a la GW. The rise of Insys is fundamentally due to the success of Fentanyl, a synthetic opioid – not a cannabinoid – used to treat cancer pain. This is a drug that has succeeded and continues to succeed for the company, and is not easily reproducible like cannabinoid compounds. GW, however, is exclusively focused on cannabinoid products, its main product being Sativex, a sublingual cannabinoid spray that has never brought the company into profitability as of yet, and is only approved for MS spasticity.

  For a number of reasons, it is unlikely that a company focused exclusively on cannabinoid pharmaceuticals will ever achieve profitability. Taking the broad view, the expenses involved in getting a drug FDA-approved are extreme, and each indication must be separately approved each time through the gauntlet. This strategy makes sense if a drug is both patentable and exclusive and a company is reasonably assured of its return on investment in the event of an FDA approval. With cannabinoids it’s not so simple, because while synthetic cannabinoids can be patented in principle, the practicality of a synthetic cannabinoid patent is very questionable. Patents are not much use when a patient can simply acquire the same natural cannabinoids in concentrated cannabis oil form or via smoking or otherwise ingesting, at much cheaper prices in most medical marijuana states, or recreational states like Colorado and Washington.

  Take the case of GW’s Epidiolex for the Orphan epilepsy indications. The rationale behind developing any Orphan drug for a rare disease is the ability to charge exorbitant sums for it after approval in order to make up for the development costs. While some are trying to compare GW’s Epidiolex with Alexion’s (ALXN) $440K a year Soliris for a rare blood disorder or Vertex’s (VRTX) $300K a year Kalydeco for cystic fibrosis, attempting to sell synthetic CBD for anywhere near that amount sounds nothing less than ludicrous. The only way people are able to pay such wild sums for Orphan drugs is that insurance companies pay. They pay because these rare drugs are absolutely exclusive to the companies that manufacture them and cannot be obtained anywhere else by any means. However, there is no way insurance companies would hand over that kind of money when access to natural high-CBD cannabis strains are readily available, almost ubiquitous. One can even get CBD paste for free, legally, at sites like NewCure.org run by activist volunteers.

  Patients and/or insurance companies paying a modest sum for the convenience of CBD in pill or spray form is one thing. But there is simply no way anyone will pay the fantastic sum necessary to recover the costs of Orphan drug development through the necessary bureaucratic pathways for readily available cannabinoids. With medical marijuana regulations being relaxed state by state and even recreational use being legalized slowly but surely, cannabinoid compounds will cease having any appeal as investible pharmaceuticals whose profits are normally obtained through real and tight-fisted exclusivity. Cannabinoids should instead be considered as agricultural commodities that happen to have medicinal uses.

  Let’s not forget that Marinol, the very first synthetic THC cannabinoid to be developed by AbbVie (ABBV) and approved in 1985, only peaked at sales of $100M in 2007 22 years after its approval before going generic, hardly anything close to blockbuster.

  That being said, the money to be made in pot stocks will be in the companies selling it as a mass-produced commodity rather than as an ultrarare Orphan drug, as well as in the satellite companies serving that industry.

  The Cannabis Security Option

  It is too early to tell which companies will succeed at growing and supplying cannabis on a mass agricultural scale, and excitement in the early stages is often misplaced, as happened with Growlife (PHOT) back in March. The litany of legal barriers getting in the way of entrepreneurs freely supplying the market, coupled with the notoriety of marijuana that generates emotional excitement, can be a dangerous combination for investment purposes.

  Nevertheless, restrictions on the market are being cleared very slowly but surely, and while these restrictions still exist mainly on the Federal level but also on the State level as well, it will be difficult for any publicly traded company to outperform. Public companies need to strictly comply with statutory authority or else risk being delisted. Such is the nature of going public. However, there is one way to use the rocky legal landscape to your advantage, and that is by way of cannabis security companies helping all manner of cannabis producers through the regulatory minefield and the abnormally high security requirements involved.

  Nearly all pot stocks except GW are microcaps, as are the security companies serving the cannabis industry. Therefore, in order to spread out risk, it makes more sense to invest in the security companies that serve both the public and privately held companies all the way down to the smallest cannabis coffee shop retailer in Colorado.

  The number one public company specializing in cannabis security by market cap is Blue Line Protection Group (BLPG). Blue Line is just starting out, but is already operating in 3 states including Colorado where it has 52 clients, Washington, and Nevada. The grey nature of the cannabis industry necessitates a cash-only environment and virtually no banking services, as credit card companies and banks are regulated by the Federal government according to which cannabis is illegal, through the interstate commerce clause of the Constitution. Meaning, credit card companies and banks cannot legally service marijuana dispensaries, necessitating a very high level of security with cash filled safes, armored transports, and tax compliance. As long as the Feds consider cannabis a schedule I drug, the all-cash environment of the business will persist and companies like Blue Line will be in demand.

  On the banking front, Blue Line has developed a proprietary method of regulatory compliance for its medical marijuana clients in Nevada through the First Security Bank of Nevada, which could open the door to Blue Line being the exclusive middleman facilitating much-needed banking services to the marijuana industry.

  Blue Line’s publicly traded competitor is a nanocap called DirectView Holdings (DIRV), which has recently targeted the cannabis sector but is materially behind Blue Line in terms of a client base.

  The further marijuana expands as a commodity, the higher the dissonance will be between Federal and State law on the issue, and the higher that dissonance, the more necessary companies like Blue Line will become. While it is difficult to know which of the pot stocks will come out on top in the end, almost all cannabusiness will need enhanced security.

  Given that GW is barking up the wrong tree treating cannabis as a pharmaceutical and the stock is severely overbought, and given that almost all others in the pot stocks sector are high risk development stage companies, the nature of Blue Line’s business plan applying to all cannabusiness spreads the risk out much more evenly than any one pot stock.

MarketExclusive – October 28, 2014 – The Volatility Index, or VIX, is known to everyone as the “Fear Index,” but ask anyone how it’s calculated and chances are they’ll give you a blank stare, say something about options, and tell you to go ask the CBOE because they invented the thing. The VIX is an obscure measuring stick indeed, some unknown animal that spikes wildly when stocks tank, but precious few can tell you how it works exactly. So if you’re a fear investor and you want something a little more straightforward and understandable, nothing lately has spiked fear in the eyes of all Americans like the Ebola virus.

There is no Ebola index as of yet, but there are a few Ebola-related stocks that act just like the VIX when fear over Ebola spikes. The one advantage is that while the VIX always trends down as market fear inevitably abates and a new trading range is reached, with Ebola stocks, there is the added potential of a higher, more stable plateau being reached if indeed Ebola becomes a serious problem.

What follows are three examples of Ebola-related companies and how their stock has responded to the news, followed by one company whose stock has not moved yet, probably because it only just recently entered this fear-driven market.

Alpha Pro Tech (NYSEMKT:APT)

Alpha Pro Tech is a small, sub $100M market cap stock that jumped from $3.15 to over $10 between October 6th and the 13th when news struck of the death of Liberian Thomas Eric Duncan on October 8th from Ebola, followed by the infection of Dallas nurse Nina Pham on October 12th, one of the hospital workers who cared for Duncan during his illness.

Up until August when the current Ebola outbreak really started hitting the news, Alpha Pro was an unremarkable company, with a small conservative business model, steady, responsible, and profitable but otherwise unexciting. Zero debt, steady cash, small and steady earnings that last year surpassed $2M for the first time, it sells construction materials, protective gear like shoe covers and gowns, and infection control apparel including face masks and eye shields. Put the latter two segments together and you have a hazmat suit.

For the quarter ended September 30th, Alpha Pro reported $13.2M (page 10) in revenue. $8.5M came from building supplies, $3.5M from protective gear, and only $1.2M from its infection control unit. Meaning, infection control accounted for less than 10% of its quarterly revenues. Then Nina Pham tested positive for Ebola and people began thinking every hospital in the country would put in a huge order for hazmat suits.

  The chart belies a clear tendency towards hysteria, but so far Alpha Pro has more than maintained its upward trend line since August by a comfortable margin. While there is certainly fear involved here, so far this is not like the VIX where once the fear dissolves, the index drifts back to its lows. There is a distinct possibility that Alpha Pro will enjoy a new plateau now that it has new attention and potentially new buyers who never paid attention to it before. While the VIX is merely a calculated aggregate, Ebola stocks are actively valued by investors on an individual basis.

Alpha Tech made another 52% jump on the news of Doctor Craig Spencer who tested positive for the virus in New York City on October 23. This time the price range for the jump was a lot narrower as the market began to make more realistic valuations. But of course, in the worst case scenario that Ebola does become a major problem in the US, those highs of October 13th will likely be reached and breached.

Lakeland Industries (NASDAQ:LAKE)

Lakeland Industries is a similar story with a similar market cap, the differences being that protective gear is Lakeland’s main focus as opposed to a tertiary division of its operations, and its earnings are erratic compared with Alpha Pro. Over the course of 20-plus year history, it has negative retained earnings. While Alpha Pro seems to have better management, Lakeland has higher revenues and focuses on protective gear across a range of industries. Meaning, Lakeland should have better access to the Ebola market than Alpha Pro.

Lakeland’s chart looks very similar to Alpha Pro’s, except its spike on October 13th is more pronounced. From October 6th to 13th, LAKE spiked 235% compared with APT’s 219%.

  Lakeland also had a stronger bounce on the October 23rd news of Dr. Spencer in New York, and the stock has continued to maintain its lead over Alpha Pro. Again, so far, the upward trend line has been handily maintained.

Tekmira Pharmaceuticals (NASDAQ:TKMR)

Tekmira Pharmaceuticals can serve as a counter example as to what kind of Ebola stocks do not resemble the VIX. Tekmira is a development stage biotech that made the Ebola news page due to its phase 1 trial for an Ebola treatment. However, scratch a bit at the surface and you’ll find that its phase 1 trial has been suspended following a clinical hold. Tekmira still bounced strongly in early October on Ebola related news, but investors quickly found out in this case that there was nothing doing.

Selling Hazmat suits is one thing. There are no regulatory barriers to selling them. Getting a drug through the clinical pipeline is something else entirely. Add onto that the fact that there already is an experimental treatment for Ebola called ZMAPP whose development has been accelerated, and there really is little reason to consider Tekmira much of an Ebola stock.

Naturalnano (OTCMKTS:NNAN)

Naturalnano, as its name suggests, is a nanocap totally off the radar of most investors, with almost nobody even realizing it has anything to do with Ebola at all. Naturalnano is a startup that focuses on nanotechnology and its applications for industry, and only recently got into the business of hazmat suits through its subsidiary ViralProtec. ViralProtec, along with the full hazmat suit itself, offers isolation units with a human remains pouch, spill kits, and donning and doffing checklist boards. In fact they announced a purchase order with a California hospital just today.

Granted, Naturalnano does not have the branding that either Lakeland or Alpha Pro has, but if the Ebola situation does continue to worsen, it is one of the only Ebola stocks that has yet to respond to current events and could have a very high upside once its hazmat division becomes accretive to earnings over the next few quarters.

Disclaimer:

Except for the historical information presented herein, matters discussed in this release contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. MarketExclusive.com is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. MarketExclusive.com may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. MarketExclusive.com may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. For full disclosure please visit: http://marketexclusive.com/about-us/disclaimer/

New Post has been published on http://www.htmluse.com/10-best-responsive-one-page-parallax-website-html5-css3-or-photoshop-psd-themes-template-or-layout-2015/

10+ Best Responsive One Page Parallax Website HTML5, CSS3 or Photoshop PSD Themes, template or layout 2015

Responsive One Page Parallax Website HTML5, CSS3 or Photoshop PSD Themes, template or layout of this generation and everyone has accepted it for its rock solid features and performance. The light weight framework has enabled the performance we require to view our website fast on our day to day mobile devices like tablets, smartphones, laptops etc. If your business needs better exposure then you might want your Responsive One Page Parallax Website HTML5, CSS3 or Photoshop PSD Themes, template or layout website to be able to access across multiple device platforms.

Responsive One Page Parallax Website HTML5, CSS3 or Photoshop PSD Themes, template or layout Responsive design is being implemented in almost every ecommerce made today either its premium. Users take extra care when buying a paid theme as they want it to be working on their mobile devices with android and ios. We have taken much time to get a quality list of Best Responsive One Page Parallax Website HTML5, CSS3 or Photoshop PSD Themes, template or layout which will look grand on multiple devices.

So whatever your device is, the below Responsive One Page Parallax Website HTML5, CSS3 or Photoshop PSD Themes, template or layout will auto resize to make your website pretty looking without any tear. Readability is also taken care into these ecommerce Themes as is is the important factor which needs to be properly assigned to the website code. This is not a huge list of junk One Page Parallax template, Themes; there are pretty quality themes which you can choose from here. Please share if you came across any new Responsive One Page Parallax Website HTML5, CSS3 or Photoshop PSD Themes, template or layout in here with us.

Anyways here in this topic you will find Responsive One Page Parallax Website HTML5, CSS3 or Photoshop PSD Themes, template or layout which are useful for your website.

——————————————————————–

  Responsive One Page Parallax Website HTML5, CSS3 or Photoshop PSD Themes, template or layout:- Iva – Retina One-Page Parallax Theme

  Download & Demo

IVA is a Onepage Multipurpose Retina ready Theme that comes with six pre-designed skins, change images, text and you are good to go. Its fully responsive and easy to customize. Theme comes with 8 different colors that you can use, but its very easy to add your colors that will fit your brand. You can use it for Agencies, Models, Businesses, Freelancers, Studios, Photographers, Lawyers and many more…

Discover the endless possibility of IVA and tryout all the variations that we have pre-designed for you. What ever your next project might be, your own website or a new website for one of your clients, IVA offers you the possibility to design the website, just the way you like it.

—————————————————————————

Responsive One Page Parallax Website HTML5, CSS3 or Photoshop PSD Themes, template or layout:- Edroma – One Page Landing Page

Download & Demo

Edroma is one page HTML5&CSS3 landing page template. It’s perfect for product or service presentation. Minimalistic design and well-considered page layout will certainly provide your page high attention of viewers.

—————————————————————————

Responsive One Page Parallax Website HTML5, CSS3 or Photoshop PSD Themes, template or layout:- Panes – WordPress on One Page

Download & Demo

We took up a challenge of building an easily customizable theme that looks unlike a typical WordPress theme.

Full screen background images, clean & elegant design and a fancy scrolling effect give your site a unique look. Panes is responsive and its skin’s elements look crisp on retina screens.

—————————————————————————

Responsive One Page Parallax Website HTML5, CSS3 or Photoshop PSD Themes, template or layout:- Morpheus – Ultimate One Page Parallax Theme

Download & Demo

This is Morpheus, your ultimate experience in One-Page Parallax themes. This is the complete solution of building fast and efficient responsive one-page/multi-page parallax websites. It will morph perfectly on your needs!

—————————————————————————

Responsive One Page Parallax Website HTML5, CSS3 or Photoshop PSD Themes, template or layout:- Ariva – Onepage for Team, Band, Group, Company

Download & Demo

—————————————————————————

Responsive One Page Parallax Website HTML5, CSS3 or Photoshop PSD Themes, template or layout:- 

Download & Demo

ARIVA is an onepage, minimal, clean and modern WordPress Theme for anyone who wants to build an amazing & modern website for their agency, company, team work, group of people, a music band, hiphop band, dancing band, dancer, freelancer team.

—————————————————————————

Responsive One Page Parallax Website HTML5, CSS3 or Photoshop PSD Themes, template or layout:- Metrika — Responsive OnePage Template

Download & Demo

Metrika» — a modern, dynamic, high-quality OnePage HTML template. Following the trends in design, we tried to create, first of all, convenient and functional product that will not take a lot of time to configure and setup. And most importantly, it will fit almost everyone. Flat design, simple and expressive animation will make your content unique. One can go to talk about all the advantages and opportunities of the template, but enough to see the live preview and everything will be understandable to you.

—————————————————————————

Responsive One Page Parallax Website HTML5, CSS3 or Photoshop PSD Themes, template or layout:- Doors Onepage MultiPurpose wordpress theme

Download & Demo

Doors is a 100% responsive and parallax one page WordPress One page Theme for corporate, agency, photography or general business. It is very clean, creative and elegant one page theme. doors is powered with Bootstrap 3.2 Framework. It can be used for creative digital agent or even personal/freelancer to show portfolios and selling services.

—————————————————————————

Responsive One Page Parallax Website HTML5, CSS3 or Photoshop PSD Themes, template or layout:- Tesla Onepage Personal/Portofolio

Download & Demo

Tesla is an one page modern and easy customizable resume/personal portofolio built with Bootstrap 3.2. It is made with HTML5, CSS3, JS, jQuery and PHP. All files are well organized and documented so anyone can use, modify or customize this template.

—————————————————————————

Responsive One Page Parallax Website HTML5, CSS3 or Photoshop PSD Themes, template or layout:- OneUp – One Page Parallax Retina WordPress Theme

Download & Demo

OneUp is a fully responsive HTML5 Retina enabled One Page WordPress Theme suitable for any kind of creative or business use. Built upon the responsive Twitter Bootstrap framework, the theme is highly optimized for both mobile and desktop platforms. One uses lazy-loading of images and compression of all required scripts, meaning not only will your website look great, but it will also be lightening fast. See below for some of the awesome features included in this theme.

New Post has been published on http://www.htmluse.com/pull-out-content-panel/

Pull-Out Content Panel

Download   Demo

This panel has been created to fit into any website with a clean and professional design. It can be fixed on the left or on the right and can contain any type of content : headings, texts, lists, images, videos, etc. The custom scrollbars packed in this menu will automatically appear when needed and if you need to add even more content, you can use the infinite carousel to scroll between each part of the panel.

You can see a simplified version in action with the live preview so be sure to check the video and the screenshots to see all the possibilities offered by this panel.

Features

Powerful sliding side panel

Left or right position

Custom automatic scrollbars

Infinite sliding carousel

Toggle elements

CSS3 animations

Styled typography

Simple working contact form

For any type of content

Font-Awesome icons

Fits into any page

Clean and professional design

Cross-browser support

Designed for desktop computers, tablets and mobiles

Documentation file included

Usages

Here are a few examples of the possible usages :

Navigation system

Simple list of links

“Contact us” section

Informations about your company

Secondary content for your site

And probably many more…

What you get

The package contains 6 HTML files showing different possibilities or usages of this panel and all the code is organized, indented and easy to read. The script comes with an uncompressed version and a minified version.

There’s also a simple contact form included, it’s ready to be used and requires only your email address to be functionnal.

Compatible Browsers

This menu has been tested on many devices and browsers to ensure a maximum compatibility : Internet Explorer, Firefox, Chrome, Opera, Safari have successfully passed the tests. Here’s a list of compatibility :

Internet Explorer 7+

Firefox 5+

Safari 4+

Chrome

Opera 10.50+

Chrome on Android

Safari on iPad and iPhone

Free Support, Free Updates

When you purchase a product on Codecanyon, you can always access it in your downloads page. There you can subscribe to receive an email and get notified if an update is available, only the last version will appear in your downloads page. Those updates are totally free !

If you encounter an issue when using my work or find a problem, you can contact me at any time from my profile page. You’ll need to be logged in to be able to access the contact form (in the sidebar). I usually reply within 24-48 hours but during holidays or week-ends, it can take more time.